奥扎格雷钠对慢性肺心病急性发作患者血清脂联素水平的影响

Effect of Ozagrel on Serum Adiponectin Level in Patients with Chronic Pulmonary Heart Disease

目的观察奥扎格雷钠对慢性肺心病急性发作患者血清脂联素水平的影响,探讨其治疗慢性肺心病急性发作的可能机制。方法将75例慢性肺心病急性发作期患者随机分为治疗组(38例)和对照组(37例)。对照组仅给予常规治疗,治疗组在接受常规治疗的同时给予奥扎格雷钠静脉滴注,1次/d,10d为1个疗程。比较两组患者治疗后的疗效;对比两组患者治疗前后血清脂联素、白介素(IL)-6、和肿瘤坏死因子α(TNF-α)水平。结果治疗后治疗组显效21例,有效13例,无效4例;对照组分别为13例、11例、13例,两组疗效间差异有统计学意义(P<0.05)。治疗前两组患者血清脂联素、IL-6和TNF-α水平间差异无统计学意义(P>0.05);治疗后治疗组血清脂联素、IL-6和TNF-α水平〔分别为(17.9±5.6)ng/L、(30.2±13.6)ng/L和(31.5±15.1ng/L)〕与对照组〔分别为(13.8±4.7)ng/L、(38.4±11.2)ng/L和(39.6±13.5)ng/L〕比较,差异有统计学意义(P<0.05)。结论奥扎格雷钠可能通过增加血清脂联素水平、降低血清IL-6及TNF-α水平来降低全身炎症反应,从而对慢性肺心病急性发作期起到治疗作用。

Objective To research the changes of circulating adiponectin in chronic pulmonary heart disease （PHD） patients with acute exacerbation, and to find out its possible mechanism. Methods Seventy - five chronic PHD patients with acute exacerbation were randomly divided into groups ozagrel treatment （ n = 38 ） and control （ n = 37 ）. Both received conventional treatment, but treatment group additional intravenous ozagrel, 1/d, 10 d for a treatment course. The curative effects were compared between 2 groups after treatment. The levels of serum adiponectin, interleukin - 6 （ IL - 6 ） , tumor necrosis factor -α （TNF -α） were determined before treatment and after. Results After treatment, marked effectiveness was noted in 21 patients, effectiveness in 13, no effectiveness in 4 in treatment group, and 13, 11, 13, respectively, in control group, the difference was significant （ P 〈 0. 05 ）. There was not significant difference in serum adiponectin, IL - 6 and TNF - α between 2 groups before treatment （P 〉0. 05）, but after treatment there was between groups treatment （ 17.9 ± 5. 6 ng/L, 30. 2 ± 13.6 ng/L, 31.5 ± 15. 1 ng/L, respectively） and control （ 13.8 ±4. 7 ng/L, 38.4± 11.2 ng/L, 39.6 ± 13.5 ng/L, respectively）. Conclusion Ozagrel may lower systemic inflammatory response by increasing serum adiponectin level and reducing levels of IL - 6 and TNF - α, to take treatment effect on acute exacerbation of chronic PHD.